

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **April 22, 2015**

---

**Tekmira Pharmaceuticals Corporation**

(Exact name of registrant as specified in its charter)

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**001-34949**  
(Commission File Number)

**980597776**  
(IRS Employer Identification No.)

**100-8900 Glenlyon Parkway  
Burnaby, British Columbia  
Canada**  
(Address of principal executive offices)

**V5J 5J8**  
(Zip Code)

Registrant's telephone number, including area code: **(604) 419-3200**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On April 22, 2015 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1. Press release dated April 22, 2015

---

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Tekmira Pharmaceuticals Corporation**

---

(Registrant)

/s/ **BRUCE G. COUSINS**

---

Bruce G. Cousins

*Executive Vice President and Chief Financial Officer*

**April 22, 2015**

---

(Date)

## **Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results**

VANCOUVER, British Columbia, April 22, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), announced that it will hold a conference call and webcast on Wednesday, May 6, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and first quarter financial results.

### **Conference Call and Webcast Information**

A live webcast of the call can be accessed through the Investor section of Tekmira's website at [www.tekmira.com](http://www.tekmira.com). Alternatively, to access the conference call, please dial 914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Tekmira website approximately two hours after the event. A replay of the conference call can be accessed by calling 404-537-3406 or 1-855-859-2056 and referencing conference ID 20892540.

### **About Tekmira**

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies.

We also have a pipeline of non-HBV assets in oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to maximize the value of our non-HBV assets in the clinic, namely: TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease; as well as our preclinical programs in metabolic disorders and filoviruses.

Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit [www.tekmira.com](http://www.tekmira.com).

CONTACT: Investors  
Adam Cutler  
Senior Vice President, Corporate Affairs  
Phone: 604.419.3200  
Email: [acutler@tekmira.com](mailto:acutler@tekmira.com)

Julie P. Rezler  
Director, Investor Relations  
& Corporate Communications  
Phone: 604-419-3200  
Email: [jrezler@tekmira.com](mailto:jrezler@tekmira.com)

Media  
Please direct all media inquiries to: [media@tekmira.com](mailto:media@tekmira.com)